p53 gene transfer does not enhance E2F-1-mediated apoptosis in human colon cancer cells.
- Author:
John M DRAUS
1
;
Mary Jane ELLIOTT
;
Cesar ATIENZA
;
Ariel STILWELL
;
Sandra L WONG
;
Yanbin DONG
;
Hailiang YANG
;
Kelly M MCMASTERS
Author Information
1. Department of Surgery, University of Louisville, James Graham Brown Cancer Center, KY 40202, USA.
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
E2F-1;
p53;
p21;
gene therapy;
apoptosis;
adenovirus;
colon cancer;
cell cycle
- MeSH:
Adenocarcinoma/*metabolism/pathology;
Adenoviridae/genetics;
Apoptosis/*physiology;
Cell Cycle;
Cell Division;
Colonic Neoplasms/*metabolism/pathology;
Comparative Study;
Cyclins;
Gene Expression;
Gene Therapy;
Gene Transfer Techniques;
*Genes, p53;
Genetic Vectors;
HT29 Cells;
Human;
Protein p53/genetics/*metabolism;
Recombinant Proteins/metabolism;
Transcription Factors/genetics/metabolism/physiology;
Tumor Cells, Cultured;
Up-Regulation
- From:Experimental & Molecular Medicine
2001;33(4):209-219
- CountryRepublic of Korea
- Language:English
-
Abstract:
E2F-1 and p53 are sequence specific transcription factors that are intimately involved in the regulation of the cell cycle. In addition to their role in cell cycle control, both E2F-1 and p53 have been identified as tumor suppressors and mediators of apoptosis. We have shown previously that adenoviral-mediated E2F-1 overexpression induces efficient apoptosis in colon adenocarcinoma cells. Previous reports have suggested that E2F-1 and p53 cooperate to mediate apoptosis and therefore, in this study, we examined the efficacy of combination gene therapy using adenovirus vectors expressing E2F-1 and p53 in human colon adenocarcinoma cell lines, HT-29 and SW620 (both mutant p53). Cells were treated by mock infection or infection with adenoviral vectors expressing b-galactosidase (LacZ), E2F-1, p53 or a combination of E2F-1 and p53. IC25 concentrations of each virus were estimated and used for each treatment in order to detect any synergistic or cooperative effects on tumor cell death in the combination therapy. By 5 days post infection, E2F-1-overexpressing cells exhibited growth inhibition and approximately 40-50% cell death in both cell lines. Co-expression of p53 with E2F-1 abrogated E2F-1-mediated growth inhibition and cell death. Cell cycle analysis revealed that overexpression of E2F-1 resulted in an accumulation of cells in G2/M phase, while overexpression of p53 resulted in a G1 phase accumulation. However, co-expression of E2F-1 and p53 counteracted each other as fewer cells accumulated in G1 and G2/M when compared to either p53 or E2F-1 alone. Furthermore, co-expression of p53 with E2F-1 resulted in decreased levels of E2F-1 protein expression. Mechanistically, upregulation of the CDK inhibitory protein, p21(WAF1/CIP1), was demonstrated in HT-29 cells following overexpression of either E2F-1, p53 or the combination E2F-1/p53 therapy. However, in SW620 cells, only the cells infected with Ad-p53 alone or in combination resulted in upregulation of p21(WAF1/CIP1). These results suggest that p53 and p21(WAF1/CIP1) may cooperate to inhibit the expression and activity of E2F-1. In conclusion, combination adenoviral vector-mediated E2F-1 and p53 gene transfer was not therapeutically advantageous in this in vitro model of human colon adenocarcinoma.
